QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Retatrutide?
Retatrutide (Triple GLP-1R/GIPR/GCGR agonist (LY3437943)) is a 39-amino acid triple-receptor peptide. Triple receptor co-agonist simultaneously activating GLP-1R, GIPR, and GCGR. GCGR activation adds thermogenesis, fatty acid oxidation, and hepatic glucose production modulation beyond dual GIP+GLP-1 agonism. Phase 2 (NEJM 2023): 24.2% mean weight reduction at 48 weeks (12mg dose).
Research Applications
Triple Receptor Pharmacology
GLP-1R + GIPR + GCGR co-agonism, additive receptor biology
GCGR Research
Isolated GCGR contribution vs tirzepatide (dual) in parallel arms
Obesity Models
Phase 2 NEJM 2023 reference — 24.2% weight reduction
Thermogenesis
GCGR-mediated fat oxidation and energy expenditure
NASH/Liver
Hepatic GCGR signalling and liver fat reduction
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not publicly standardized |
| Molecular Formula | Large synthetic peptide (sequence-specific; proprietary) |
| Peptide Type | Triple Receptor Agonist (GLP-1 / GIP / Glucagon Receptors) |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | As indicated by manufacturer |




